Literature DB >> 25545762

Ingenol mebutate gel treatment for actinic cheilitis: report of four cases.

Nerea Barrado Solís1, Paula Molés Poveda, César Lloret Ruiz, Virginia Pont Sanjuan, Manel Velasco Pastor, Esther Quecedo Estébanez, Javier Miquel Miquel.   

Abstract

Actinic cheilitis (AC) are premalignant lesions that have an increased risk of malignant transformation. Their treatment, therefore, is essential to prevent carcinogenesis. However, optimal therapy is not well established and different modalities yield variable results. Ingenol mebutate gel has recently been approved by the US Food and Drug Administration for topical treatment of actinic keratosis, with high clearance rates. On the basis of these findings, we report our experience with this drug for the treatment of AC.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  actinic cheilitis; field-directed therapy; ingenol mebutate gel

Mesh:

Substances:

Year:  2014        PMID: 25545762     DOI: 10.1111/dth.12188

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  Ingenol Mebutate Topical Gel A Status Report On Clinical Use Beyond Actinic Keratosis.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2016-11

2.  Daylight photodynamic therapy for the management of actinic cheilitis.

Authors:  Dimitrios Andreadis; Achilleia -Maria Pavlou; Efstratios Vakirlis; Eleftherios Anagnostou; Fotini Vrani; Athanasios Poulopoulos; Alexandros Kolokotronis; Dimitrios Ioannidis; Elena Sotiriou
Journal:  Arch Dermatol Res       Date:  2020-04-07       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.